Articles

Clinical trials specifically targeting young patients with breast cancer are necessary. Read More ›

An internationally collaborated study revealed a decreased risk of cancer among children whose parents lived beyond average life spans. Read More ›

Brown University researchers show throat and vocal cords are better protected when heartburn is treated with antacids. Read More ›

UC Irvine researchers isolate markers for the detection of prostate cancer in urine. Read More ›

Animal study shows higher percentage of drug delivered to lungs via inhalation. Read More ›

Novel drugs developed by UT Southwestern Medical Center researchers interrupt androgen receptor signaling. Read More ›

This is the third article in a 4-part series on bendamustine. While the previous article discussed the efficacy of bendamustine for patients with chronic lymphocytic leukemia (CLL) and non-Hodgkin lymphoma (NHL) in the registration studies cited in the US product labeling, this article discusses its safety Read More ›

Bendamustine is an active chemotherapy agent approved by the FDA for the treatment of patients with chronic lymphocytic leukemia (CLL) and for specific populations of patients with non-Hodgkin lymphoma (NHL). Read More ›

Bendamustine is approved for single-agent use in chronic lymphocytic leukemia (CLL) based on the result from a phase 3 trial comparing bendamustine and chlorambucil. Read More ›

The previous articles have outlined the clinical outcomes of clinical trials evaluating bendamustine in chronic lymphocytic leukemia (CLL) and non-Hodg­kin lymphoma (NHL). The third in the series of articles discusses the short-term toxicities of bendamustine from these clinical trials. Read More ›